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Inherited and acquired defects in homologous
recombination, a phenotype termed ‘BRCAness’, may
lend to therapeutic exploitation in breast cancer. To this
end, development and clinical evaluation of platforms to
identify signatures of BRCAness are of immense interest.
In this issue of Breast Cancer Research, Vollebergh and
colleagues report that a BRCA-like array comparative
genomic hybridization (aCGH) genomic instability
signature is associated with benefit from high-dose
cyclophosphamide-thiotepa-carboplatin chemotherapy.
We discuss the strengths and weaknesses of this study
and consider the clinical significance and applicability
of this aCGH BRCAness signature in the context of
other existing homologous recombination deficiency
detection platforms.autologous stem cell support in patients with at leastIn this issue of Breast Cancer Research, Vollebergh and
colleagues [1] report on the predictive capacity of an
array comparative genomic hybridization (aCGH) signa-
ture resembling BRCA1- and BRCA2-mutant breast can-
cers. The BRCA1 and BRCA2 genes are required for
DNA double-strand break (DSB) and interstrand cross-
link repair by homologous recombination (HR) [2,3].
Pre-clinical and clinical data suggest that cancers arising
in BRCA1 and BRCA2 mutation carriers are particularly
responsive to agents that lead to DSBs (for example,
platinum salts and poly(ADP-ribose) polymerase (PARP)
inhibitors) [4-6]. Although inherited mutations in
BRCA1 and BRCA2 account for only 5 % to 10 % of all
breast cancers, these and other genes which operate in
the HR pathway may be altered by mutation,* Correspondence: psharma2@kumc.edu
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article, unless otherwise stated.rearrangement, DNA methylation, or attenuated mRNA
expression, resulting in impairment of HR in a signifi-
cant proportion of patients with breast cancer. Inactiva-
tion of HR by these mechanisms in BRCA-wild-type
cancers (a phenotype termed ‘BRCAness’) may induce a
similar hypersensitivity to DNA-damaging agents which
can be therapeutically exploited. To this end, development
and clinical evaluation of platforms to identify signatures
of BRCAness have recently been a subject of intense in-
vestigation, especially in triple-negative breast cancer
(TNBC), a subtype thought to be enriched for BRCAness
[7-9].
Vollebergh and colleagues retrospectively assessed
a subset of HER-2-negative tumor specimens from
a randomized clinical trial that compared five cycles
of 5-fluorouracil-epirubicin-cyclophosphamide (FE90C)
with four cycles of FE90C followed by high-dose
cyclophosphamide-thiotepa-carboplatin (HD-CTC) with
four positive axillary lymph nodes. The BRCA1- and
BRCA2-like aCGH profiles were based on previous work
by this group and were generated on 249 HER-2-
negative formalin-fixed paraffin-embedded (FFPE) tumor
samples [10]. Overall, the BRCA-likecgh profile was de-
tected in 32 % (12 % BRCA1-like, 15 % BRCA2-like, and
5 % both BRCA1- and BRCA2-like) of the study cohort
and predicted benefit from HD-CTC in both TNBC and
hormone receptor-positive breast cancer. HD-CTC was
associated with improved overall survival compared with
FE90C in patients with BRCA-like
cgh tumors but not in
patients with non-BRCA-likecgh tumors. As expected, a
significant proportion (76 %) of TNBCs harbored the
BRCA-likecgh profile. Interestingly, 28 % of hormone
receptor-positive tumors also demonstrated the BRCA-
likecgh profile. This aCGH platform is attractive as it al-
lows detection of genomic instability resulting from HR
deficiency without requiring identification of the precise
molecular etiology. If validated in other cohorts, thisCentral Ltd. This is an Open Access article distributed under the terms of the
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benefit from intensified DNA-damaging therapy.
Despite the future potential of this aCGH platform
as a predictive marker, the present study has important
limitations. First, the HD-CTC regimen included both
carboplatin and intensified alkylating chemotherapy
(cyclophosphamide and thiotepa) and therefore it
remains unclear whether the benefit observed in the
BRCA-likecgh patients within the experimental cohort
was due to the platinum or the intensified alkylating
agents or both. This is a significant confounder and
complicates interpretation of these data. Additionally,
although this study included a high-risk population
(at least four positive nodes), neither the experimental
(HD-CTC) nor the control (taxane-devoid chemother-
apy) regimens are considered standard for node-positive
breast cancer in this era. Evaluation of this assay in cohorts
treated with contemporary neoadjuvant chemotherapy reg-
imens is encouraged.
Currently, a standard platform for detecting BRCAness
has not reached routine clinical application, but several
functional assays besides the aCGH platform described
by Vollebergh and colleagues have emerged. The hom-
ologous recombination deficiency (HRD) assay devel-
oped by Myriad Genetics, Inc. (Salt Lake City, UT, USA)
evaluates tumor genome loss of heterozygosity, telo-
meric allelic imbalance (TAI), and large-scale state tran-
sitions, which are all indirect measures of tumor
genomic instability. High HRD scores are highly corre-
lated with defects in BRCA1/2 and are associated with
sensitivity to neoadjuvant platinum-based chemotherapy
in TNBC [9,11]. Another study examining TAI in spor-
adic TNBC has shown that tumors with high levels of
TAI respond better to neoadjuvant platinum chemother-
apy [7]. In addition to exhibiting genomic instability, tu-
mors with BRCAness may exhibit characteristic gene
expression patterns. Mulligan and colleagues [8] recently
reported on a 44-gene DNA damage response deficiency
signature (DDRDS) which was developed in cohorts
enriched for germline BRCA1/2 and Fanconi anemia mu-
tations. The DDRDS is enriched for immune response-
related genes and predicted favorable response to FE90C
chemotherapy in both TNBC and hormone receptor-
positive breast cancer. The aCGH, HRD, TAI, and DDRDS
platforms are all compatible with FFPE tissues, making
them suitable for prospective studies. Furthermore, all of
these HR deficiency platforms suggest that the BRCAness
phenotype exists in at least half of patients with TNBC
and one quarter of patients with hormone receptor-
positive breast cancer, implying future predictive applic-
ability to a large fraction of patients with breast cancer.
There is now renewed interest in the efficacy of plat-
inum agents for the treatment of TNBC as recent ran-
domized trials have demonstrated improvement inpathological complete response rates with the addition
of neoadjuvant carboplatin to anthracycline/taxane-
based chemotherapy [12-14]. HR deficiency assay assess-
ments on the completed randomized neoadjuvant plat-
inum trials are eagerly awaited and will help identify
patients most likely to benefit from such an approach.
Whether HR deficiency assays will predict benefit from
PARP inhibitors in addition to DNA-damaging chemo-
therapy also remains to be seen.
Employing functional measures of HR pathway defi-
ciency rather than relying on documented changes in
specific genes should capture more patients who might
benefit from DNA-damaging therapies, and Vollebergh
and colleagues should be congratulated on developing
one such assay. However, before HR deficiency assays
can be used for medical utility, the recognized steps
for incorporation of predictive biomarkers into clinical
care (that is, additional validation studies and assessment
within prospective randomized trials) have to be fulfilled
[15]. If appropriately validated, HR deficiency assays could
have tremendous impact on patient care by identifying
patients most likely to benefit from DNA-damaging agents
like platinum salts or PARP inhibitors or both.
In conclusion, considerable strides have been made in
analytical development and early clinical validation of
functional HR deficiency assays and these efforts bring
us one step closer to the eventual utilization of BRCA-
ness as a guide to personalize treatment with DNA-
damaging agents in patients with breast cancer.
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